Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Net Margin (2020 - 2025)

Historic Net Margin for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to 47.04%.

  • Apellis Pharmaceuticals' Net Margin rose 762300.0% to 47.04% in Q3 2025 from the same period last year, while for Sep 2025 it was 4.43%, marking a year-over-year increase of 394000.0%. This contributed to the annual value of 25.32% for FY2024, which is 1079700.0% up from last year.
  • Latest data reveals that Apellis Pharmaceuticals reported Net Margin of 47.04% as of Q3 2025, which was up 762300.0% from 23.63% recorded in Q2 2025.
  • Over the past 5 years, Apellis Pharmaceuticals' Net Margin peaked at 47.04% during Q3 2025, and registered a low of 35183.15% during Q2 2021.
  • Its 5-year average for Net Margin is 2403.3%, with a median of 127.77% in 2023.
  • The largest annual percentage gain for Apellis Pharmaceuticals' Net Margin in the last 5 years was 342275200bps (2022), contrasted with its biggest fall of -4870600bps (2022).
  • Apellis Pharmaceuticals' Net Margin (Quarter) stood at 245.37% in 2021, then crashed by -199bps to 732.43% in 2022, then skyrocketed by 92bps to 60.51% in 2023, then soared by 72bps to 17.09% in 2024, then surged by 375bps to 47.04% in 2025.
  • Its Net Margin stands at 47.04% for Q3 2025, versus 23.63% for Q2 2025 and 55.29% for Q1 2025.